Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 20, 2026, 11:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 386 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glaucoma, Open-Angle Clear all
Completed Phase 2 Interventional Results available

A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure

NCT05451329
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
VVN539 Ophthalmic Solution 0.02%, VVN539 Ophthalmic Solution 0.04%, VVN539 Ophthalmic Solution Vehicle
Drug
Lead sponsor
VivaVision Biotech, Inc
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Jul 20, 2026, 11:22 PM EDT
Recruiting Not applicable Interventional

Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy

NCT06313749
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Open Angle Glaucoma
Interventions
Minimally Invasive Micro Sclerostomy Device
Device
Lead sponsor
Sanoculis Ltd
Industry
Eligibility
40 Years to 85 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Jul 20, 2026, 11:22 PM EDT
Completed No phase listed Observational

Evaluation and Treatment of Pediatric, Developmental, and Genetic Eye Diseases

NCT00076271
View directory record Official record
Conditions
Eye Diseases
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Denver, Colorado • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 20, 2026, 11:22 PM EDT
Terminated Not applicable Interventional Results available

A Prospective, Multicenter Study of the OMNI® Surgical System in Pseudophakic Eyes With Open Angle Glaucoma

NCT04465630
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
OMNI® Surgical System
Device
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
22 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
Fayetteville, Arkansas • Newport Beach, California • Petaluma, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Jul 20, 2026, 11:22 PM EDT
Terminated No phase listed Observational

Effects of Selective Laser Trabeculoplasty

NCT00986141
View directory record Official record
Conditions
Glaucoma
Interventions
Surgery, Selective Laser Trabeculoplasty
Procedure
Lead sponsor
University of Kentucky
Other
Eligibility
40 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced Jul 20, 2026, 11:22 PM EDT
Completed No phase listed Observational

Comparative Effectiveness of Treatment Strategies for Primary Open-Angle Glaucoma

NCT01645319
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
Agency for Healthcare Research and Quality (AHRQ)
Federal
Eligibility
18 Years and older
Enrollment
2,597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Jul 20, 2026, 11:22 PM EDT
Active, not recruiting No phase listed Observational

A Real-World Study of Interventional Clinical Outcomes in Patients With Open Angle Glaucoma and Other Chronic Eye Diseases

NCT07216677
View directory record Official record
Conditions
Glaucoma, AMD, Diabetic Retinopathy (DR)
Interventions
Chronic Disease Intervention CDI
Other
Lead sponsor
Interstat LLC
Other
Eligibility
18 Years to 99 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 20, 2026, 11:22 PM EDT
Completed Phase 3 Interventional Results available

Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT02558400
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) Ophthalmic Solution 0.02%, Latanoprost Ophthalmic Solution 0.005%
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Jul 20, 2026, 11:22 PM EDT
Not listed Phase 3 Interventional

Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure

NCT05165290
View directory record Official record
Conditions
Elevated Intraocular Pressure
Interventions
Latanoprost ophthalmic solution, 0.005%, TC-002 latanoprost ophthalmic solution, 0.005%
Drug
Lead sponsor
TearClear Corp
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
20
States / cities
Garden Grove, California • Glendale, California • Mission Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Jul 20, 2026, 11:22 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Topical Insulin for Glaucoma (TING2)

NCT07619482
View directory record Official record
Conditions
Open Angle Glaucoma, Primary Open Angle Glaucoma, Low Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions
EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month), Vehicle Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 20, 2026, 11:22 PM EDT
Completed Phase 3 Interventional Results available

Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%

NCT03519386
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
G2-TR intraocular implant containing travoprost, Sham surgery + active-comparator eye drops
Combination Product · Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Jul 20, 2026, 11:22 PM EDT
Completed No phase listed Observational

Determinants of Compliance With Glaucoma Therapy

NCT00362622
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 15, 2012 · Synced Jul 20, 2026, 11:22 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension

NCT02247804
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Bimatoprost SR, Active Comparator: Timolol 0.5%, Sham: Applicator Without Needle, Timolol Vehicle (placebo)
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
56
States / cities
Phoenix, Arizona • Glendale, California • Irvine, California + 51 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Jul 20, 2026, 11:22 PM EDT
Completed Not applicable Interventional

Multicenter Study Using Glaukos® Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction With Cataract Surgery

NCT01461291
View directory record Official record
Conditions
Primary Open-angle Glaucoma
Interventions
iStent inject, Cataract surgery
Device · Procedure
Lead sponsor
Glaukos Corporation
Industry
Eligibility
45 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Racine, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Jul 20, 2026, 11:22 PM EDT
Completed Phase 2 Interventional

Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

NCT02136940
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension, Eye Disease
Interventions
AMA0076, Placebo
Drug
Lead sponsor
Amakem, NV
Industry
Eligibility
30 Years to 85 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
9
States / cities
Artesia, California • Inglewood, California • Petaluma, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2015 · Synced Jul 20, 2026, 11:22 PM EDT
Completed Phase 2 Interventional Results available

An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product

NCT02143843
View directory record Official record
Conditions
Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost
Drug
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Artesia, California • La Jolla, California • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Jul 20, 2026, 11:22 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

NCT04499248
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
AGN-193408 SR, Lumigan, Sham Administration, Lumigan Vehicle
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
42
States / cities
Sun City, Arizona • Glendale, California • Inglewood, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 20, 2026, 11:22 PM EDT
Not yet recruiting Phase 4 Interventional

Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)

NCT07048886
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Rocklatan (netarsudil 0.02% and latanoprost 0.005%), Systane
Drug
Lead sponsor
Center for Sight Las Vegas
Other
Eligibility
40 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Jul 20, 2026, 11:22 PM EDT
Completed Phase 2 Interventional

24-hour Efficacy of AR-12286

NCT01330979
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
AR-12286 0.5% Ophthalmic Solution
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Jul 20, 2026, 11:22 PM EDT
Terminated Not applicable Interventional Results available

A Post-market Study Of Use Of The OMNI® Surgical System In Open Angle Glaucoma

NCT04616573
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
OMNI® Surgical System, iStent inject
Device
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
22 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Dothan, Alabama • Vineland, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Jul 20, 2026, 11:22 PM EDT
Terminated Not applicable Interventional

Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser Trabeculoplasty

NCT02327312
View directory record Official record
Conditions
Primary Open-Angle Glaucoma
Interventions
Stents, Laser, Laser Trabeculoplasty
Device · Procedure
Lead sponsor
Glaukos Corporation
Industry
Eligibility
35 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
9
States / cities
Glendale, Arizona • Fayetteville, Arkansas • Hemet, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Jul 20, 2026, 11:22 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension

NCT00947661
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
SPARC0912, Reference0912
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Jul 20, 2026, 11:22 PM EDT
Terminated Not applicable Interventional

Multicenter Ab-interno Glaucoma Study Investigating Canaloplasty

NCT04769453
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Canaloplasty using the iTrack microcatheter with Healon GV Pro, Canaloplasty using the Omni surgical system with Healon GV Pro, Canaloplasty using the iTrack microcatheter with Healon Pro, Canaloplasty using the Omni surgical system with Healon Pro
Device
Lead sponsor
Nova Eye, Inc.
Industry
Eligibility
22 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Glendale, Arizona • Beverly Hills, California • Orange, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Jul 20, 2026, 11:22 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®

NCT00799682
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Xalatan, Travatan Z
Drug
Lead sponsor
Ophthalmic Consultants of Long Island
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
5
States / cities
East Meadow, New York • Lynbrook, New York • Rockville Centre, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Jul 20, 2026, 11:22 PM EDT